TempraMed Enters into Exclusive Kuwait Distribution Agreement, Expanding Gulf Region Commercial Footprint
Toronto, Ontario--(Newsfile Corp. - October 15, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has executed a definitive exclusive distribution agreement dated September 14, 2026 (the "Distribution Agreement") with OGM For Import Medicine and Medical Supplies (the "Distributor
Technology, Biotechnology, Pharmaceuticals, Health
2026-10-15 3:05 AM EDT | TempraMed Technologies Ltd.
Biosenta Commences TRUE(TM) Testing with Dynamic Facility Services
Calgary, Alberta--(Newsfile Corp. - October 13, 2026) - Biosenta Inc. (CSE: ZRO) ("Biosenta" or the "Company") announces that it has commenced testing of its TRUE™ disinfectant with Dynamic Facility Services Ltd. ("Dynamic"), advancing the commercial pilot program previously announced on September 1, 2026. TRUE™ has now been deployed at two locations serviced by Dynamic - an office building and a commercial operation - to evaluate defined applications under real-world operat
Biotechnology, Chemical, Household / Consumer / Cosmetics
2026-10-13 10:59 PM EDT | Biosenta Inc.
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient), representing a critical operational and strategic milestone as the Company advances PH-762 to the next
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-13 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP facility Milestone demonstrates BioHarvest's ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercialization High-potency proprietary olive-derived Verbascoside composition demonstra
Biotechnology, Pharmaceuticals, Health
2026-10-13 7:00 AM EDT | BioHarvest Sciences Inc.
Envoy Medical Submits Second Module of Modular Premarket Approval Application to FDA for Breakthrough Designated Acclaim(R) Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - October 12, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fu
Biotechnology, Healthcare and Hospitals
2026-10-12 8:30 AM EDT | Envoy Medical, Inc.
Theralase(R) to Present at ThinkEquity Conference
Toronto, Ontario--(Newsfile Corp. - October 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of proprietary Energy-Activated Small Molecules ("EASMs") for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the Company has been invited to present at the 2026 Thin
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-10-09 7:00 AM EDT | Theralase Technologies Inc.
Entheon Announces Continuance into British Columbia
Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has continued out of the jurisdiction of Canada under the Canada Business Corporations Act into the provincial jurisdiction of British Columbia under the Business Corporations Act (British Columbia) (the "BCBCA"). Shareholders approved the continuance at the Company's an
Biotechnology, Cannabis, Psychedelics, Cannabis Ancillary Service Provider
2026-10-08 6:49 PM EDT | Entheon Biomedical Corp.
TMC Group Reports Progress on Capacity Expansion Ahead of EANM 2026
Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - Earlier this year, TMC Group, a Canadian manufacturer of enriched stable isotopes, announced plans to increase production capacity by 50 percent. Today, the company is commissioning new production lines that are already producing material, marking an early milestone in that work. The company will be exhibiting at the European Association of Nuclear Medicine (EANM) Annual Congress in Vienna next week, where the team will c
Technology, Biotechnology, Chemical, Pharmaceuticals
2026-10-08 12:00 PM EDT | TMC Group
Enoumena Therapeutics and AOP Health Announce Exclusive Canadian Commercialization Agreement for SIBBORAN(R) (landiolol)
Quebec and Vienna, Austria--(Newsfile Corp. - October 8, 2026) - Enoumena Therapeutics Inc. and AOP Health today announced an exclusive commercialization agreement to expand Canadian institutional access to PrSIBBORAN® (landiolol hydrochloride), an ultra-short-acting, selective beta-1 adrenergic receptor blocker. Authorized by Health Canada in 2023, SIBBORAN is indicated for the short-term reduction of ventricular rate in patients with supraventricular tachycar
Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-10-08 10:47 AM EDT | Enoumena Therapeutics Inc.
Enoumena Therapeutics et AOP Health annoncent une entente exclusive de commercialisation au Canada de SIBBORAN(R) (landiolol)
Québec et Vienne, Autriche--(Newsfile Corp. - 8 octobre 2026) - Enoumena Therapeutics Inc. et AOP Health ont annoncé aujourd'hui la conclusion d'une entente exclusive de commercialisation visant à élargir l'accès des établissements de santé canadiens à PrSIBBORAN® (chlorhydrate de landiolol), un bêtabloquant sélectif des récepteurs bêta-1 adrénergiques à action ultra-courte. Autorisé par Sant
Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-10-08 10:47 AM EDT | Enoumena Therapeutics Inc.
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Nova Scotia
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - October 7, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that the Breast Health Research Unit (BHRU) at IWK Health has joined as the second Canadian site in its large multi-center observational data collection study to advan
Technology, Biotechnology, Healthcare and Hospitals, Health
2026-10-08 10:01 AM EDT | Breathe BioMedical Inc.
Illumisoft Appoints Former 3M Growth Ventures Leader Bill Weber as Chief Strategy Officer
Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - Illumisoft Lighting Corp. (TSXV: UVC) (OTCQB: FUVCF) ("Illumisoft" or the "Company") announces the appointment of Bill Weber as Chief Strategy Officer, effective October 7, 2026. Mr. Weber will work with Chief Executive Officer Ehsan Agahi and the leadership team on corporate strategy, commercial priorities, strategic partnerships and market development as Illumisoft advances commercialization of its SaniLume upper-room
Technology, Biotechnology, Healthcare and Hospitals, Household / Consumer / Cosmetics
2026-10-08 9:27 AM EDT | Illumisoft Lighting Corp.
Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme
British Columbia and Rehovot, Israel--(Newsfile Corp. - October 8, 2026) - Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, and BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (BioHarvest), today announced an important milestone in their next-generation sweetener development programme. The programme has demonstrated that BioHarvest's Botanical Synthesis™ platform is capable of producing the targeted ne
Biotechnology, Pharmaceuticals, Health
2026-10-08 8:00 AM EDT | BioHarvest Sciences Inc.
Zenith Epigenetics Receives FDA Clearance for Registration Enabling Study of ZEN-3694 in NUT Carcinoma
Calgary, Alberta--(Newsfile Corp. - October 8, 2026) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") today announced that the Company has received clearance from the US Food and Drug Administration ("FDA") to sponsor a registration enabling study for ZEN-3694, the Company's clinical oncology candidate, for the treatment of NUT carcinoma. Zenith and the FDA concur on the design of the randomized trial, which will compare the combination of ZEN-3694 and a CKD4/6 inhibitor to the best avai
2026-10-08 7:15 AM EDT | Zenith Capital Corp.
TempraMed Granted Mexican Patent for Newest Product, VIVI Box
Highlights Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets Supports commercialization strategy and strategic engagement with appliance manufacturers across America's premium refrigeration sector Patent term extends through Octobe
Technology, Biotechnology, Pharmaceuticals, Health
2026-10-08 3:05 AM EDT | TempraMed Technologies Ltd.
Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the National Longevity and Regenerative Therapy Board of The Bahamas (LARTA Board), including ethics approval from the LARTA Ethics Committee, for its commercial Phase 1 study of VesCell™as a treatment for angina, vascular dementia and pain. This milestone advances the Company's clinical developmen
Biotechnology, Pharmaceuticals, Health
2026-10-07 2:37 PM EDT | Hemostemix Inc.
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma
Grasonville, Maryland--(Newsfile Corp. - October 7, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that its wholly-owned animal health subsidiary, OSAH received feedback f
2026-10-07 8:30 AM EDT | OS Therapies
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Nova Scotia
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - October 7, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that the Breast Health Research Unit (BHRU) at IWK Health has joined as the second Canadian site in its large multi-center observational data collection study to advan
Technology, Biotechnology, Healthcare and Hospitals, Health
2026-10-07 8:00 AM EDT | Breathe BioMedical Inc.
PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies
Toronto, Ontario--(Newsfile Corp. - October 7, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company advancing 3D-printed medicines, today announced the launch of the M3DICINES™ National Network Program (the "Network Program"). The program will build a national network of qualified sites that make personalized medicines on CraftMake™ pharmaceutical 3D printers, supported by PharmaTher's M3DICINES&#
Biotechnology, Pharmaceuticals
2026-10-07 8:00 AM EDT | PharmaTher Holdings Ltd.
Palindrome Pharma Launches in Canada to Unlock Access to High-Quality Biosimilar Medicines
Toronto, Ontario--(Newsfile Corp. - October 7, 2026) - Palindrome Pharma, a new pharmaceutical company focused on biosimilar medicines, today announced its launch in Canada, with a mission to broaden access to high-quality biologic therapies and contribute to a more sustainable Canadian healthcare system. As demand for biologic medicines continues to grow, biosimilars have an important role to play in creating greater choices for Canadians. Palindrome Pharma will work with global and C
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-07 12:30 AM EDT | Palindrome Pharma Inc.